Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Discovery of Biomarker Pattern for Alzheimer s Disease

NEW YORK, Nov. 10 (GenomeWeb News) - Ciphergen Biosystems said today that it has discovered a biomarker pattern that correctly classified more than 96 percent of Alzheimer's disease patents and more than 94 percent of normal individuals using a four peak pattern of markers.

 

The company said the findings were presented at the Society for Neuroscience's annual meeting in New Orleans.

 

Ciphergen said that researchers analyzed cerebrospinal fluid from probable Alzheimer's diease pateints and age-matched normal individuals using the company's SELDI ProteinChip biomarker system and Expression Difference Mapping methodology.

 

Of the 39 candidate biomarkers found to be overexpressed among the Alzheimer's disease sufferers, a pattern of four was selected and used to correctly classify 29 of out 30 Alzheimer's disease patients and 33 of 35 normal individuals.

 

Ciphergen said that additional studies looking at more than 200 additional samples are underway to validate the markers' utility in diagnosing early-stage Alzheimer's disease and differentiating the condition from other dementias. 

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.